TGFB1 and cancer: Specifically, inhibitors targeting the TGF-β signalling pathway hold potential not only in unravelling its intricate interactions with other signalling pathways, but also in the development of novel therapeutic strategies for a wide array of cancer types (Morikawa et al., 2016 ▸).